Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies.
Severe thrombotic alterations, such as veno-occlusive disease of the liver, may occur in the early phase following high-dose chemoradiotherapy and BMT. In this study, performed in patients with hematological malignancies subjected to allogeneic (10 cases) and autologous (20 cases) BMT, we have monitored laboratory hemostatic parameters to better understand the pathogenetic mechanism of thrombosis and particularly of veno-occlusive disease. Prothrombin time, activated partial thromboplastin time, plasma fibrinogen, markers of hypercoagulability (thrombin-antithrombin complex and prothrombin fragment F1+2); natural anticoagulants (protein C, protein S and antithrombin) together with fibrinolytic parameters (plasminogen, alpha 2-antiplasmin, tissue-plasminogen activator, plasminogen activator inhibitor and D-dimer) were assessed before transplant, on day 0 and weekly for 1 month thereafter. A hypercoagulability state, not related to an impairment of the anticoagulant and fibrinolytic systems, was documented before and after autologous and allogeneic transplant. Two patients developed veno-occlusive disease: they did not show any difference from the other patients before transplant while they presented a decrease of the natural anticoagulants along with altered fibrinolytic parameters only at the clinical onset of veno-occlusive disease. In conclusion, in this study a state of marked hypercoagulability was documented in BMT patients and the hemostatic laboratory parameters evaluated were not able to predict the occurrence of the thrombotic complications.
Catani
L
L
Institute of Hematology L. & A. Seràgnoli, University of Bologna, Italy.
Gugliotta
L
L
Mattioli Belmonte
M
M
Vianelli
N
N
Gherlinzoni
F
F
Miggiano
M C
MC
Belardinelli
A R
AR
Rosti
G
G
Calori
E
E
Bandini
G
G
D000990:Antithrombin III / Q000032:analysis; D001778:Blood Coagulation Disorders / Q000150:complications*; D001780:Blood Coagulation Tests; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D004198:Disease Susceptibility; D005260:Female; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007938:Leukemia / Q000097:blood* / Q000601:surgery; D008223:Lymphoma / Q000097:blood* / Q000601:surgery; D008297:Male; D009101:Multiple Myeloma / Q000097:blood* / Q000601:surgery; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D013927:Thrombosis / Q000209:etiology; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases